pharma · Primary Sclerosing Cholangitis (PSC) · No medical condition.
Dr. Falk Pharma
Dr. Falk Pharma GmbH
Dr. Falk Pharma is a pharma organization headquartered in Freiburg im Breisgau, DE. Primary therapeutic focus areas include Primary Sclerosing Cholangitis (PSC), No medical condition., eosinophilic esophagitis, Celiac Di
Company details
- Status
- Public
- HQ
- Leinenweberstraße 5, Freiburg im Breisgau, Baden-Württemberg 79108, DE
- Employees
- 399
- Programs
- 11
- Drugs
- 15
- Patents
- 0
Budenofalk 4 mg Zäpfchen, placebo to test
Phase 2 · small molecule · Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
Budenofalk 4 mg Zäpfchen, placebo to test for Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma is a Phase 2 program (small_molecule) at Dr. Falk Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code BUS-006/RAP
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dr. Falk Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
- Status
- active
- Trials
- 1